London UK, Philadelphia USA April 26, 2019 — GSK today announced that the US Food and Drug Administration (FDA) has approved, under priority review, the use of the intravenous (IV) formulation of Benlysta (belimumab), a B-lymphocyte stimulator…Original Article
GSK Receives US Approval of Benlysta for Intravenous Use in Children with Lupus Aged Five Years and Above
